Progyny, Inc. (PGNY): R&D Expense

Annual figures by period end, from SEC filings.

$9.50M

Year ended 2025-12-31

$11.80M

Trailing 12 months to 2026-06-30

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$9.50M	n/a	2026-02-27, From 2025-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Misc Health & Allied Services, NEC), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Progyny, Inc. (PGNY)	2025-12-31	$9.50M	n/a
Viemed Healthcare, Inc. (VMD)	2025-12-31	$3.02M	-1.7%
Cryo Cell International Inc (CCEL)	2025-11-30	$376.3K	-69.7%
Marpai, Inc. (MRAI)	2025-12-31	$7.0K	-75.9%
BioRestorative Therapies, Inc. (BRTX)	2025-12-31	$10.09M	+50.5%

Compare PGNY, VMD, CCEL, MRAI side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗